Dual Roles of IL-27 in Cancer Biology and Immunotherapy

Marina Fabbi, Grazia Carbotti, Silvano Ferrini

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

IL-27 is a pleiotropic two-chain cytokine, composed of EBI3 and IL-27p28 subunits, which is structurally related to both IL-12 and IL-6 cytokine families. IL-27 acts through a heterodimer receptor consisting of IL-27Rα (WSX1) and gp130 chains, which mediate signaling predominantly through STAT1 and STAT3. IL-27 was initially reported as an immune-enhancing cytokine that supports CD4+ T cell proliferation, T helper (Th)1 cell differentiation, and IFN-γ production, acting in concert with IL-12. However, subsequent studies demonstrated that IL-27 displays complex immune-regulatory functions, which may result in either proinflammatory or anti-inflammatory effects in relationship to the biological context and experimental models considered. Several pieces of evidence, obtained in preclinical tumor models, indicated that IL-27 has a potent antitumor activity, related not only to the induction of tumor-specific Th1 and cytotoxic T lymphocyte (CTL) responses but also to direct inhibitory effects on tumor cell proliferation, survival, invasiveness, and angiogenic potential. Nonetheless, given its immune-regulatory functions, the effects of IL-27 on cancer may be dual and protumor effects may also occur. Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.

Original languageEnglish
Article number3958069
JournalMediators of Inflammation
Volume2017
DOIs
Publication statusPublished - 2017

Fingerprint

Interleukin-27
Immunotherapy
Neoplasms
Interleukin-12
Cytokines
Cell Proliferation
Biological Models
Th1 Cells
Cytotoxic T-Lymphocytes
Antigen-Antibody Complex
Cell Differentiation
Interleukin-6
Cell Survival
Anti-Inflammatory Agents
Theoretical Models
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Dual Roles of IL-27 in Cancer Biology and Immunotherapy. / Fabbi, Marina; Carbotti, Grazia; Ferrini, Silvano.

In: Mediators of Inflammation, Vol. 2017, 3958069, 2017.

Research output: Contribution to journalReview article

Fabbi, Marina ; Carbotti, Grazia ; Ferrini, Silvano. / Dual Roles of IL-27 in Cancer Biology and Immunotherapy. In: Mediators of Inflammation. 2017 ; Vol. 2017.
@article{ba10d0f8cea6455d82d2f7f09d66c3e2,
title = "Dual Roles of IL-27 in Cancer Biology and Immunotherapy",
abstract = "IL-27 is a pleiotropic two-chain cytokine, composed of EBI3 and IL-27p28 subunits, which is structurally related to both IL-12 and IL-6 cytokine families. IL-27 acts through a heterodimer receptor consisting of IL-27Rα (WSX1) and gp130 chains, which mediate signaling predominantly through STAT1 and STAT3. IL-27 was initially reported as an immune-enhancing cytokine that supports CD4+ T cell proliferation, T helper (Th)1 cell differentiation, and IFN-γ production, acting in concert with IL-12. However, subsequent studies demonstrated that IL-27 displays complex immune-regulatory functions, which may result in either proinflammatory or anti-inflammatory effects in relationship to the biological context and experimental models considered. Several pieces of evidence, obtained in preclinical tumor models, indicated that IL-27 has a potent antitumor activity, related not only to the induction of tumor-specific Th1 and cytotoxic T lymphocyte (CTL) responses but also to direct inhibitory effects on tumor cell proliferation, survival, invasiveness, and angiogenic potential. Nonetheless, given its immune-regulatory functions, the effects of IL-27 on cancer may be dual and protumor effects may also occur. Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.",
author = "Marina Fabbi and Grazia Carbotti and Silvano Ferrini",
year = "2017",
doi = "10.1155/2017/3958069",
language = "English",
volume = "2017",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Dual Roles of IL-27 in Cancer Biology and Immunotherapy

AU - Fabbi, Marina

AU - Carbotti, Grazia

AU - Ferrini, Silvano

PY - 2017

Y1 - 2017

N2 - IL-27 is a pleiotropic two-chain cytokine, composed of EBI3 and IL-27p28 subunits, which is structurally related to both IL-12 and IL-6 cytokine families. IL-27 acts through a heterodimer receptor consisting of IL-27Rα (WSX1) and gp130 chains, which mediate signaling predominantly through STAT1 and STAT3. IL-27 was initially reported as an immune-enhancing cytokine that supports CD4+ T cell proliferation, T helper (Th)1 cell differentiation, and IFN-γ production, acting in concert with IL-12. However, subsequent studies demonstrated that IL-27 displays complex immune-regulatory functions, which may result in either proinflammatory or anti-inflammatory effects in relationship to the biological context and experimental models considered. Several pieces of evidence, obtained in preclinical tumor models, indicated that IL-27 has a potent antitumor activity, related not only to the induction of tumor-specific Th1 and cytotoxic T lymphocyte (CTL) responses but also to direct inhibitory effects on tumor cell proliferation, survival, invasiveness, and angiogenic potential. Nonetheless, given its immune-regulatory functions, the effects of IL-27 on cancer may be dual and protumor effects may also occur. Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.

AB - IL-27 is a pleiotropic two-chain cytokine, composed of EBI3 and IL-27p28 subunits, which is structurally related to both IL-12 and IL-6 cytokine families. IL-27 acts through a heterodimer receptor consisting of IL-27Rα (WSX1) and gp130 chains, which mediate signaling predominantly through STAT1 and STAT3. IL-27 was initially reported as an immune-enhancing cytokine that supports CD4+ T cell proliferation, T helper (Th)1 cell differentiation, and IFN-γ production, acting in concert with IL-12. However, subsequent studies demonstrated that IL-27 displays complex immune-regulatory functions, which may result in either proinflammatory or anti-inflammatory effects in relationship to the biological context and experimental models considered. Several pieces of evidence, obtained in preclinical tumor models, indicated that IL-27 has a potent antitumor activity, related not only to the induction of tumor-specific Th1 and cytotoxic T lymphocyte (CTL) responses but also to direct inhibitory effects on tumor cell proliferation, survival, invasiveness, and angiogenic potential. Nonetheless, given its immune-regulatory functions, the effects of IL-27 on cancer may be dual and protumor effects may also occur. Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85013296186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013296186&partnerID=8YFLogxK

U2 - 10.1155/2017/3958069

DO - 10.1155/2017/3958069

M3 - Review article

AN - SCOPUS:85013296186

VL - 2017

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 3958069

ER -